New Houston med school to offer low-cost health care thanks to $1M gift

for the people

As the new UH medical school welcomes its second class, it's also planning for a new facility to support low-cost care. Photo via UH.edu

The University of Houston College of Medicine has announced it will open a low-cost health care facility thanks to a $1 million gift from The Cullen Trust for Health Care.

UHCOM will open the direct primary care clinic on the campus of Memorial Hermann Southwest Hospital, and, according to a news release from UH, it's only just the beginning of a network of clinics focused on treating those without health insurance.

"A direct primary care practice will add value to the local health care ecosystem by tackling one of the most pressing problems of our city: the lack of a comprehensive primary care system for the uninsured," says UH President Renu Khator in the release. "The Cullen Trust for Health Care shares our commitment to improving the overall health and health care of the population of Greater Houston and we are grateful for their support."

The direct primary care, or DPC, model is an alternative to insurance-based and fee-based care and eliminates third party payers. Instead, patients pay a monthly membership to receive primary care services — including telehealth, basic office procedures, at-cost laboratory testing, and access to medications at reduced prices. The clinic will offer same-day or next-day appointments as a guarantee and be staffed by faculty physicians and UH health professions students.

"The UH College of Medicine wants to restore primary care as the foundation of health care. We have developed a model with strong incentives to innovate the delivery of primary care designed to improve quality and more effectively control the cost of care," says Dr. Stephen Spann, founding dean of the UH College of Medicine, in the release. "We are building our model upon the four pillars of access, population health, social determinants of health and trusting relationships. In this framework, the physician is accountable for the health of their member panel and will demonstrate long-term cost and quality outcomes."

Dr. Stephen Spann is the founding dean of the UH College of Medicine. Photo via UH.edu

Founded in 2020, UHCOM's brief existence has been supported by generous donors – including a foundational $50 million gift as well as an endowment. This latest funding is from The Cullen Trust for Health Care — established in 1978 as an organization that grants financial assistance to institutions providing health care services in the Greater Houston area.

"The Cullen Trust for Health Care is proud to support this pilot endeavoring to bring a new form of patient-centered primary care to Houston's underserved communities. We are hopeful that the new UH College of Medicine direct primary care clinic will proactively engage patients to increase utilization and improve continuity of care," says Cullen Geiselman, chairman of the board for The Cullen Trust for Health Care.

This week, the school also announced its second-ever class of students. The UHCOM class of 2025 includes 30 students selected out of about 6,000 applicants. According to a news release, more than half of the second cohort received a $100,000 four-year scholarship. The future doctors will be celebrated with a White Coat Ceremony on Saturday, July 31, at the Hilton University of Houston.

More than half — 67 percent — of the new class is female and 60 percent of the group are Black or Hispanic. Sixty-three percent represent low socioeconomic status (as defined by Texas Medical Dental Schools Application Services).

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."
View All Listings